Hospital
Cleveland Tennessee Hospital Company LLC
Cleveland Tennessee Hospital Company LLC was paid $16.31M by Medicaid between Jan 2018 and Jul 2024, across 117 billing codes. Its largest line is 99283, emergency room visit (moderate) — 30% of everything it billed.
33Billing provider infoCLEVELAND TENNESSEE HOSPITAL COMPANY LLC
CLEVELAND, TN 37311
CLEVELAND, TN 37311
33aNPI1790756203assigned 02/01/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.31M
24GClaims438,210
24DCodes billed117
24AFirst – last monthJan 2018 – Jul 2024
Compared with peers
Next to other General Acute Care Hospital providers in Tennessee
Rank by total paid#16 of 71
Median peer was paid$6.96M
This provider vs. median2.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 79,131 | $2.77M | |
| 2019 | 84,749 | $3.04M | |
| 2020 | 58,983 | $2.30M | |
| 2021 | 55,056 | $2.43M | |
| 2022 | 52,693 | $2.09M | |
| 2023 | 70,928 | $2.39M | |
| 2024incomplete | 36,670 | $1.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 30% | 40,110 | 37,254 | $4.93M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 32,248 | 29,304 | $4.86M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 13,865 | 12,308 | $2.40M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.9% | 9,172 | 8,658 | $802K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.7% | 1,056 | 992 | $285K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 46,025 | 39,068 | $229K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 10,346 | 9,048 | $192K |
| 84484 | 1.2% | 14,262 | 8,941 | $189K | |
| 80053 | Comprehensive metabolic panel | 1.0% | 43,089 | 37,001 | $170K |
| G0378 | Hospital observation service, per hour | <1% | 1,480 | 1,182 | $162K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 5,790 | 5,204 | $148K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,985 | 3,569 | $140K |
105 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,534 | $127K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,819 | $122K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 9,795 | $102K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,607 | $101K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 338 | $94K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,525 | $87K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,963 | $85K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,900 | $83K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,816 | $81K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,553 | $78K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,840 | $76K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 144 | $72K |
| 36415 | Collection of venous blood by venipuncture | <1% | 50,564 | $72K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,951 | $61K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,485 | $52K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,060 | $51K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,731 | $44K |
| 83690 | <1% | 7,677 | $40K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,599 | $36K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 27 | $35K |
| 84703 | <1% | 4,452 | $31K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 757 | $29K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,025 | $28K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 987 | $22K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 784 | $22K |
| 97597 | <1% | 666 | $17K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 237 | $15K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,384 | $11K |
| 81001 | <1% | 11,559 | $11K | |
| 81003 | <1% | 12,645 | $10K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 95 | $9K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 321 | $8K |
| 83605 | <1% | 1,355 | $8K | |
| 82550 | <1% | 1,391 | $6K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 508 | $6K |
| 94761 | <1% | 1,103 | $5K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 15 | $4K |
| 87040 | <1% | 604 | $4K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,118 | $4K |
| 81025 | <1% | 1,309 | $4K | |
| 83735 | <1% | 1,287 | $4K | |
| 87807 | <1% | 415 | $3K | |
| 86003 | <1% | 24 | $3K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 181 | $2K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 43 | $2K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 51 | $2K |
| 86900 | <1% | 292 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $2K |
| 86850 | <1% | 292 | $2K | |
| 82553 | <1% | 850 | $2K | |
| 59025 | Fetal non-stress test | <1% | 15 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 271 | $2K |
| 82962 | <1% | 726 | $2K | |
| 84145 | <1% | 290 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 315 | $2K |
| 29581 | <1% | 61 | $1K | |
| 71250 | <1% | 27 | $1K | |
| 80061 | Lipid panel | <1% | 89 | $1K |
| 82784 | <1% | 40 | $1K | |
| 85610 | <1% | 487 | $998.74 | |
| 85027 | <1% | 230 | $940.80 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 421 | $873.28 |
| 85730 | <1% | 227 | $872.11 | |
| 94760 | <1% | 658 | $849.04 | |
| 86901 | <1% | 292 | $772.85 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 133 | $666.00 |
| 96376 | <1% | 55 | $653.23 | |
| 82077 | <1% | 115 | $588.55 | |
| 84100 | <1% | 327 | $454.22 | |
| 87634 | <1% | 14 | $403.64 | |
| 74022 | <1% | 28 | $389.06 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 508 | $333.01 |
| 87070 | <1% | 99 | $315.12 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 389 | $274.49 |
| 88312 | <1% | 240 | $271.39 | |
| 84702 | <1% | 12 | $254.04 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 17 | $252.42 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 340 | $248.45 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 50 | $246.70 |
| 86364 | <1% | 29 | $245.69 | |
| 83880 | <1% | 14 | $244.55 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 609 | $239.40 |
| 73630 | <1% | 28 | $224.06 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12 | $221.72 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,754 | $210.20 |
| 84439 | <1% | 29 | $209.28 | |
| 73562 | <1% | 27 | $173.04 | |
| 72110 | <1% | 41 | $171.65 | |
| 85651 | <1% | 29 | $164.43 | |
| 87186 | <1% | 13 | $145.92 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,464 | $123.79 |
| 73610 | <1% | 25 | $122.10 | |
| 86140 | <1% | 14 | $102.12 | |
| 80143 | <1% | 13 | $100.45 | |
| 87077 | <1% | 13 | $78.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 293 | $53.33 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 113 | $28.83 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 733 | $22.54 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 12 | $17.85 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 330 | $15.00 |
| 87147 | <1% | 16 | $14.56 | |
| J2704 | Injection, propofol, 10 mg | 0% | 1,442 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 455 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 80 | $0.00 |
| L8699 | Prosthetic implant, not otherwise specified | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Northwest Hospital LLC | Tucson, AZ | $47.81M |
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.